National Institutes of Health

Description

The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way that would allow us to tackle AD/ADRD from multiple fronts in a single person, akin to what has been successful in infectious disease or cancer. This FOA will support applications that test hypotheses of possible beneficial interactions of known targets as well as understanding the mechanisms of interaction in the R61. The R33 would support rigorous validation of the proposed multi-target approach (one drug or biologic targeting multiple pathways; and/or a combination of therapies) to support future multi-target therapy development efforts. Successful grantees will be in position to apply for IGNITE or other similar translational grant mechanisms.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH Grants Information<br/>grantsinfo@nih.gov
grantsinfo@nih.gov